Share Price and Basic Stock Data
Last Updated: January 20, 2026, 11:13 pm
| PEG Ratio | -0.27 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dipna Pharmachem Ltd operates in the pharmaceuticals sector, with its share price currently standing at ₹14.8 and a market capitalization of ₹38.9 Cr. The company reported sales of ₹100 Cr for the financial year ending March 2023, reflecting a substantial increase from ₹73 Cr in the previous year. For the fiscal year ending March 2024, sales are projected to rise to ₹164 Cr, showcasing a robust growth trajectory. The quarterly sales data highlights a consistent upward trend, with ₹74 Cr reported in both September 2023 and March 2024. This stability in sales indicates a solid market presence, particularly in the competitive pharmaceutical landscape, where growth rates can vary significantly. Overall, the company’s revenue growth aligns well with industry expectations, as the pharmaceutical sector in India has been increasingly resilient, with a reported CAGR of 12-15% over recent years. This positions Dipna Pharmachem favorably among its peers.
Profitability and Efficiency Metrics
Dipna Pharmachem’s profitability metrics indicate a mixed performance. The operating profit margin (OPM) stood at 2% for March 2023, which is modest compared to industry norms. However, there has been an improvement in operational efficiency, as the OPM is expected to rise to 6% by March 2025, demonstrating a positive trend. The net profit for the year ending March 2023 was ₹1 Cr, with earnings per share (EPS) reported at ₹0.37. The company has maintained a return on equity (ROE) of 2.55%, reflecting a cautious approach to capital utilization. The interest coverage ratio (ICR) of 1.71x suggests that while the company can meet its interest obligations, it does so with limited buffer. Furthermore, the cash conversion cycle has improved significantly, standing at -20 days for March 2025, indicating efficient management of working capital. Overall, while profitability is on the rise, the margins remain thin compared to the broader industry standards.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dipna Pharmachem showcases a moderate level of financial health. The company reported reserves of ₹35 Cr, a significant increase from ₹12 Cr in March 2023, indicating a strengthening capital base. Total borrowings stood at ₹14 Cr, down from ₹19 Cr in March 2024, suggesting effective debt management. The debt-to-equity ratio is 0.44x, indicating a balanced approach to financing. Additionally, Dipna’s current ratio is 1.56x, above the typical threshold of 1.5, which signifies adequate liquidity to cover short-term liabilities. The price-to-book value (P/BV) ratio is 0.89x, which suggests that the stock is trading below its book value, potentially indicating an undervaluation in the market. However, the return on capital employed (ROCE) is recorded at 6.64%, which is below the sector average, underscoring the need for improved operational efficiency to enhance returns on investments.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dipna Pharmachem reveals a significant shift in ownership dynamics. As of September 2025, public shareholders hold 90.87% of the company, a dramatic increase from 33.45% in September 2022, indicating a transition towards more retail-led ownership. Promoters’ stake has declined to 9.13%, down from 66.56% in September 2022, which may raise concerns regarding management control and strategic direction. The number of shareholders has increased to 1,741, reflecting growing interest from retail investors. This shift towards public ownership could signal a positive outlook for investor confidence in the company’s growth prospects. However, the significant reduction in promoter holding may also suggest a lack of confidence from the original owners, which could influence market perceptions negatively. Thus, while the increasing public interest is a strength, the declining promoter stake poses a risk to overall investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Dipna Pharmachem is poised for growth, primarily driven by increasing sales and improving operational efficiency. However, the company faces several risks that could impact its performance. The thin profit margins, coupled with a low return on equity, highlight the need for strategic initiatives to enhance profitability. Moreover, the significant decrease in promoter holding raises questions about future management strategies and governance, which could affect investor confidence. The pharmaceutical sector is also subject to regulatory changes and competitive pressures that may impact profitability. If the company can navigate these challenges effectively and leverage its growing public shareholder base, it stands a chance to improve its market position. However, the management must focus on enhancing operational efficiencies and restoring investor confidence in its leadership to ensure sustained growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 120 Cr. | 95.1 | 205/84.3 | 26.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,638 Cr. | 334 | 479/192 | 75.4 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.2 Cr. | 43.4 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.7 Cr. | 40.1 | 41.0/17.0 | 140 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,513.40 Cr | 1,087.69 | 50.89 | 202.18 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 44 | 49 | 74 | 74 | 90 | 91 | 34 | 74 |
| Expenses | 28 | 42 | 48 | 73 | 73 | 88 | 89 | 32 | 71 |
| Operating Profit | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 3 |
| OPM % | 3% | 3% | 2% | 2% | 2% | 2% | 2% | 6% | 4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 2 |
| Tax % | 25% | 26% | 26% | 27% | 27% | 21% | 26% | 34% | 26% |
| Net Profit | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| EPS in Rs | 33.00 | 84.00 | 0.13 | 0.24 | 0.24 | 0.20 | 0.14 | 0.27 | 0.59 |
Last Updated: January 8, 2026, 6:16 pm
Below is a detailed analysis of the quarterly data for Dipna Pharmachem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 74.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 40.00 Cr..
- For Expenses, as of Sep 2025, the value is 71.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.00 Cr. (Mar 2025) to 71.00 Cr., marking an increase of 39.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Sep 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 6.00% (Mar 2025) to 4.00%, marking a decrease of 2.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 34.00% (Mar 2025) to 26.00%, marking a decrease of 8.00%.
- For Net Profit, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.59. The value appears strong and on an upward trend. It has increased from 0.27 (Mar 2025) to 0.59, marking an increase of 0.32.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:50 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 | 108 |
| Expenses | 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 | 103 |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 5 |
| OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% | 3% | 5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 3 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% | |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.40 | 0.86 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Dipna Pharmachem Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 20% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 74% |
| 3 Years: | -6% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 142% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:45 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 | 24 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 | 35 |
| Borrowings | 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | 14 |
| Other Liabilities | 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 | 105 |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
Below is a detailed analysis of the balance sheet data for Dipna Pharmachem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 17.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 105.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 77.00 Cr. (Mar 2025) to 105.00 Cr., marking an increase of 28.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 177.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
- For Total Assets, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
Notably, the Reserves (35.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -6.00 | -10.00 | -12.00 | -8.00 | -14.00 | -16.00 | -13.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 |
| ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Diluted EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Cash EPS (Rs.) | 0.40 | 0.45 | 0.77 | 335.17 | 8.97 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Revenue From Operations / Share (Rs.) | 51.95 | 68.34 | 83.48 | 20787.26 | 8857.11 |
| PBDIT / Share (Rs.) | 1.43 | 1.43 | 1.96 | 644.23 | 118.66 |
| PBIT / Share (Rs.) | 1.43 | 1.42 | 1.95 | 642.46 | 116.60 |
| PBT / Share (Rs.) | 0.59 | 0.59 | 1.15 | 449.80 | 15.71 |
| Net Profit / Share (Rs.) | 0.40 | 0.45 | 0.76 | 333.40 | 6.91 |
| PBDIT Margin (%) | 2.75 | 2.08 | 2.35 | 3.09 | 1.33 |
| PBIT Margin (%) | 2.75 | 2.07 | 2.33 | 3.09 | 1.31 |
| PBT Margin (%) | 1.13 | 0.86 | 1.38 | 2.16 | 0.17 |
| Net Profit Margin (%) | 0.77 | 0.66 | 0.91 | 1.60 | 0.07 |
| Return on Networth / Equity (%) | 2.53 | 2.89 | 3.74 | 67.11 | 4.23 |
| Return on Capital Employeed (%) | 7.25 | 6.82 | 6.06 | 44.39 | 9.58 |
| Return On Assets (%) | 0.73 | 0.81 | 1.17 | 3.22 | 0.09 |
| Long Term Debt / Equity (X) | 0.23 | 0.33 | 0.58 | 1.91 | 6.44 |
| Total Debt / Equity (X) | 0.44 | 0.51 | 0.65 | 5.86 | 21.74 |
| Asset Turnover Ratio (%) | 0.94 | 1.56 | 1.76 | 2.38 | 1.43 |
| Current Ratio (X) | 1.56 | 1.60 | 1.99 | 1.16 | 1.21 |
| Quick Ratio (X) | 1.23 | 1.15 | 1.50 | 0.95 | 0.85 |
| Inventory Turnover Ratio (X) | 3.85 | 5.84 | 0.00 | 10.03 | 4.90 |
| Interest Coverage Ratio (X) | 1.71 | 1.72 | 2.46 | 3.34 | 1.18 |
| Interest Coverage Ratio (Post Tax) (X) | 1.48 | 1.54 | 1.95 | 2.73 | 1.07 |
| Enterprise Value (Cr.) | 51.18 | 28.22 | 25.24 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.17 | 0.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | 14.85 | 8.22 | 10.74 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| Price / BV (X) | 0.89 | 0.60 | 0.61 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| EarningsYield | 0.02 | 0.04 | 0.06 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dipna Pharmachem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 3. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 51.95. It has decreased from 68.34 (Mar 24) to 51.95, marking a decrease of 16.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. There is no change compared to the previous period (Mar 24) which recorded 1.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.43, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.08 (Mar 24) to 2.75, marking an increase of 0.67.
- For PBIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.07 (Mar 24) to 2.75, marking an increase of 0.68.
- For PBT Margin (%), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 10. It has increased from 0.86 (Mar 24) to 1.13, marking an increase of 0.27.
- For Net Profit Margin (%), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.53. This value is below the healthy minimum of 15. It has decreased from 2.89 (Mar 24) to 2.53, marking a decrease of 0.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 6.82 (Mar 24) to 7.25, marking an increase of 0.43.
- For Return On Assets (%), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 24) to 0.73, marking a decrease of 0.08.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.33 (Mar 24) to 0.23, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has decreased from 1.56 (Mar 24) to 0.94, marking a decrease of 0.62.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.56, marking a decrease of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 1.23, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 4. It has decreased from 5.84 (Mar 24) to 3.85, marking a decrease of 1.99.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.71. This value is below the healthy minimum of 3. It has decreased from 1.72 (Mar 24) to 1.71, marking a decrease of 0.01.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 3. It has decreased from 1.54 (Mar 24) to 1.48, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 51.18. It has increased from 28.22 (Mar 24) to 51.18, marking an increase of 22.96.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.17 (Mar 24) to 0.40, marking an increase of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 8.22 (Mar 24) to 14.85, marking an increase of 6.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For Price / BV (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.60 (Mar 24) to 0.89, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dipna Pharmachem Ltd:
- Net Profit Margin: 0.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.25% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.53% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.48
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.23
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.1 (Industry average Stock P/E: 50.89)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A/211, Siddhi Vinayak Complex, Ahmedabad Gujarat 380055 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Keyur Dipakkumar Shah | Managing Director |
| Ms. Dipna Keyur Shah | Non Executive Director |
| Mr. Nirav Soni | Non Executive Director |
| Mr. Nandish Shaileshbhai Jani | Independent Director |
| Mr. Parin Bhavsar | Independent Director |
FAQ
What is the intrinsic value of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd's intrinsic value (as of 21 January 2026) is ₹3.26 which is 75.49% lower the current market price of ₹13.30, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹35.0 Cr. market cap, FY2025-2026 high/low of ₹26.3/11.4, reserves of ₹35 Cr, and liabilities of ₹177 Cr.
What is the Market Cap of Dipna Pharmachem Ltd?
The Market Cap of Dipna Pharmachem Ltd is 35.0 Cr..
What is the current Stock Price of Dipna Pharmachem Ltd as on 21 January 2026?
The current stock price of Dipna Pharmachem Ltd as on 21 January 2026 is ₹13.3.
What is the High / Low of Dipna Pharmachem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dipna Pharmachem Ltd stocks is ₹26.3/11.4.
What is the Stock P/E of Dipna Pharmachem Ltd?
The Stock P/E of Dipna Pharmachem Ltd is 17.1.
What is the Book Value of Dipna Pharmachem Ltd?
The Book Value of Dipna Pharmachem Ltd is 24.5.
What is the Dividend Yield of Dipna Pharmachem Ltd?
The Dividend Yield of Dipna Pharmachem Ltd is 0.00 %.
What is the ROCE of Dipna Pharmachem Ltd?
The ROCE of Dipna Pharmachem Ltd is 6.64 %.
What is the ROE of Dipna Pharmachem Ltd?
The ROE of Dipna Pharmachem Ltd is 2.55 %.
What is the Face Value of Dipna Pharmachem Ltd?
The Face Value of Dipna Pharmachem Ltd is 10.0.